Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation

Journal of Internal Medicine

Volumn 244, Issue 1, 1998, Pages 79-82

  Astermark, J ^a   Bjorgell O ^b   Linden E ^a   Lethagen, S ^a   Nilsson, P ^b   Berntorp, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Calf vein thrombosis, oral anticoagulation; Recurrence rate

Indexed keywords

DALTEPARIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MALE; MIDDLE AGED; RECURRENCE; THROMBOPHLEBITIS; WARFARIN;

EID: 0031858102     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00318.x     Document Type: Article

References (15)

1. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Int Med 1992; 232: 155-60.
2. Lagerstedt CI, Olsson C-G, Fagher BO, Öqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-8.
3. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-84.
4. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
5. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J et al. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
6. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
7. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
8. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S et al. Low-molecular-weight heparin (Enoxaprin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
9. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
10. Coon WW, Willis PW, Symons MJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1969; 170: 559-68.
11. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 1986; 81: 255-9.
12. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-802.
13. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (Factor V Leiden). N Engl J Med 1997; 336: 399-403.
14. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102: 312-26S.
15. Raskob G. Calf-Vein Thrombosis in Disorders of Thrombosis. (Hull & Pineo, eds). Saunders, 1996; 398-405.